J. Greg Slatter

Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.

C. Krejsa, A. P. Plumb, Ric Barker, 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Phase 1 Concentration‐QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT‐232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia

M. Allard, B. Poland, J. Greg Slatter, 2021, Clinical pharmacology in drug development.

Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222

J. Gibbs, H. Tu, R. Greene, 2011, Xenobiotica; the fate of foreign compounds in biological systems.